Lacey B. Robinson

2.8k total citations · 3 hit papers
52 papers, 1.2k citations indexed

About

Lacey B. Robinson is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Immunology and Allergy. According to data from OpenAlex, Lacey B. Robinson has authored 52 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 20 papers in Physiology and 12 papers in Immunology and Allergy. Recurrent topics in Lacey B. Robinson's work include Asthma and respiratory diseases (20 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (16 papers) and Food Allergy and Anaphylaxis Research (11 papers). Lacey B. Robinson is often cited by papers focused on Asthma and respiratory diseases (20 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (16 papers) and Food Allergy and Anaphylaxis Research (11 papers). Lacey B. Robinson collaborates with scholars based in United States, United Kingdom and Germany. Lacey B. Robinson's co-authors include Kimberly G. Blumenthal, Rachel L. Miller, Aleena Banerji, Paige G. Wickner, Carlos A. Camargo, Rebecca R. Saff, Anna R. Wolfson, Aidan A. Long, David A. Khan and Elizabeth Phillips and has published in prestigious journals such as New England Journal of Medicine, JAMA and SHILAP Revista de lepidopterología.

In The Last Decade

Lacey B. Robinson

45 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acute Allergic Reactions to mRNA COVID-19 Vaccines

2021 167 citations Kimberly G. Blumenthal, Lacey B. Robinson et al. profile →
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation

2024 102 citations Surya P. Bhatt, Klaus F. Rabe et al. profile →
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials

2025 18 citations Surya P. Bhatt, Klaus F. Rabe et al. The Lancet Respiratory Medicine profile →

Peers

Lacey B. Robinson

PHARM

PRM

PHYSI

Philippe Bégin Canada

Stuart L. Abramson United States

Suwat Benjaponpitak Thailand

Mattia Giovannini Italy

Joshua L. Kennedy United States

Beverly G. Mellen United States

Stanley M. Fìneman United States

Yuma Fukutomi Japan

Emily C. McGowan United States

Stefania Arasi Italy

Philippe Bégin Canada

Lacey B. Robinson

268 ×0.6

341 ×1.0

PHARM

1.2k ×4.1

180 ×0.7

PRM

655 ×3.4

PHYSI

Citations per year, relative to Lacey B. Robinson Lacey B. Robinson (= 1×) peers Philippe Bégin

Countries citing papers authored by Lacey B. Robinson

Since Specialization

Citations

This map shows the geographic impact of Lacey B. Robinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lacey B. Robinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lacey B. Robinson more than expected).

Fields of papers citing papers by Lacey B. Robinson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lacey B. Robinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lacey B. Robinson. The network helps show where Lacey B. Robinson may publish in the future.

Co-authorship network of co-authors of Lacey B. Robinson

This figure shows the co-authorship network connecting the top 25 collaborators of Lacey B. Robinson. A scholar is included among the top collaborators of Lacey B. Robinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lacey B. Robinson. Lacey B. Robinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhong, Nanshan, Sahajal Dhooria, Haohui Fang, et al.. (2025). Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia–Pacific Region. Clinical & Experimental Allergy. 55(8). 691–700. 1 indexed citations

Robinson, Lacey B., et al.. (2025). National Trends in Hospitalizations for Appendectomy in Children, 2001-2017. Türk anesteziyoloji ve reanimasyon derneği dergisi. 53(3). 122–131.

Christenson, Stephanie A., Nicola A. Hanania, Surya P. Bhatt, et al.. (2025). Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine. 13(8). 687–697. 5 indexed citations

Bhatt, Surya P., Klaus F. Rabe, Nicola A. Hanania, et al.. (2025). Dupilumab Improves Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS. CHEST Journal. 168(1). 56–66. 1 indexed citations

Bourdin, Arnaud, Jonathan Corren, Anand Shah, et al.. (2025). Dupilumab efficacy in patients with asthma and allergic bronchopulmonary aspergillosis (ABPA). OA2337–OA2337.

Bafadhel, Mona, Stephanie A. Christenson, Claus Vogelmeier, et al.. (2024). IN PATIENTS WITH MODERATE OR SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION, DUPILUMAB DOES NOT IMPACT BLOOD EOSINOPHIL LEVELS: PHASE 3 BOREAS TRIAL. CHEST Journal. 166(4). A4831–A4834. 1 indexed citations

Papi, Alberto, Nicola A. Hanania, Surya P. Bhatt, et al.. (2024). Dupilumab Improves Pre-bronchodilator Lung Function Measures in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation: Data From the Phase 3 Boreas Trial. A1199–A1199. 1 indexed citations

Vogelmeier, Claus, Mona Bafadhel, Stephanie A. Christenson, et al.. (2024). DUPILUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND TYPE 2 INFLAMMATION: THE PHASE 3 NOTUS TRIAL. CHEST Journal. 166(4). A4814–A4818. 1 indexed citations

Vogelmeier, Claus, Mona Bafadhel, Stephanie A. Christenson, et al.. (2024). DUPILUMAB REDUCES EXACERBATIONS AND IMPROVES LUNG FUNCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND EMPHYSEMA. CHEST Journal. 166(4). A4809–A4813. 1 indexed citations

10.

Bhatt, Surya P., Klaus F. Rabe, Nicola A. Hanania, et al.. (2024). Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS). Respiratory Medicine. 236. 107846–107846.

11.

Geller, Ruth J., et al.. (2023). Application of Asthma Prediction Tools in a Cohort of Infants with Severe Bronchiolitis. Pediatric Allergy Immunology and Pulmonology. 36(3). 110–114.

12.

Robinson, Lacey B. & Melanie A. Ruffner. (2022). Proton Pump Inhibitors in Allergy: Benefits and Risks. The Journal of Allergy and Clinical Immunology In Practice. 10(12). 3117–3123. 5 indexed citations

13.

Robinson, Lacey B., Janice A. Espinola, Ruth J. Geller, et al.. (2021). Early Introduction of Food Allergens and Risk of Developing Food Allergy. Nutrients. 13(7). 2318–2318. 18 indexed citations

14.

Zheng, David X., Ruth J. Geller, Lacey B. Robinson, Markus D. Boos, & Carlos A. Camargo. (2021). A comparison of case definitions for infant atopic dermatitis in a multicenter prospective cohort study. Health Science Reports. 4(3). e324–e324. 3 indexed citations

15.

Robinson, Lacey B., et al.. (2021). Trends in US Emergency Department Visits for Anaphylaxis Among Infants and Toddlers: 2006-2015. The Journal of Allergy and Clinical Immunology In Practice. 9(5). 1931–1938.e2. 22 indexed citations

16.

Robinson, Lacey B., Adam Landman, Erica S. Shenoy, et al.. (2021). Allergic symptoms after mRNA COVID-19 vaccination and risk of incomplete vaccination. The Journal of Allergy and Clinical Immunology In Practice. 9(8). 3200–3202.e1. 19 indexed citations

17.

Robinson, Lacey B., Xiaoqing Fu, Ingrid V. Bassett, et al.. (2020). COVID-19 severity in hospitalized patients with asthma: A matched cohort study. The Journal of Allergy and Clinical Immunology In Practice. 9(1). 497–500. 20 indexed citations

18.

Miller, Rachel L., et al.. (2019). Advances in drug allergy, urticaria, angioedema, and anaphylaxis in 2018. Journal of Allergy and Clinical Immunology. 144(2). 381–392. 17 indexed citations

19.

Adegunsoye, Ayodeji, Justin M. Oldham, Evans R. Fernández Pérez, et al.. (2017). Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. ERJ Open Research. 3(3). 16–2017. 82 indexed citations

20.

Robinson, Lacey B. & Rachel L. Miller. (2015). The Impact of Bisphenol A and Phthalates on Allergy, Asthma, and Immune Function: a Review of Latest Findings. Current Environmental Health Reports. 2(4). 379–387. 130 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact